Comparative evaluation of economic effi ciency of modern inhaled anesthetics

The purpose of presented retrospective analysis was to identify retrospectively and estimate the economic benefits that can occur when comparing the costs of using desflurane or sevoflurane for anesthesia during surgery. Formalization and evaluation were carried out in accordance with the industry standard “Health technology assessment”, approved and signed into law June 14, 2014 by Order of the Federal Agency for Technical Regulation and Metrology of the Russian Federation GOST №568-art and ISPOR recommendations, and meet the requirements of statistical significance, allowing to develop recommendation conclusions on the use of each product in any given situation. Pharmacoeconomic evaluation is based on data from official registration licenses and patient information leaflets, randomized controlled clinical trials data and information on value, pricing and costs obtained from the public independent sources. In accordance with the objectives, indications and limitations on the use of these drugs for anesthesia, the target population of this study were patients of diff erent ages, who required the use of inhalation anesthesia during the ongoing surgical procedures: patients with physiological status not higher than Class I (ASA I) on the scale of the American Association of Anesthesiologists. Compared medical technologies were III generation inhalation analgesics Sevorane and Suprane. Th ere was conducted a cost-effectiveness analysis of the inhalation anesthetics, during which cost of achieving the minimum alveolar concentration (MAC) using compared inhaled anesthetic drugs was estimated. The analysis showed that the difference in favor of desflurane is 155.72 rub for a four-hour operation. The most significant influence on the direct medical costs associated with the use of inhalation anesthesia was shown by the cost of inhalation anesthetic (gas) per 1 ml, the concentration of the gas, the flow rate of fresh gas, duration of anesthesia. Sensitivity analysis confirmed the data obtained. In the current situation of the retrospective evaluation the assumed shift from sevoflurane to desflurane in 1 000 patients aged 12 to 60 years that require inhalation anesthesia, will be accompanied by cost savings of 102,907 rub to 155,720 rub, and with the use of induction of anesthesia with propofol up to 162 900 rub. Whereas during anesthesia in newborns and patients older than 60 years shift of desflurane to sevoflurane in 1 000 patients will reduce the cost by 266,354 rub and 225,672 rub respectively. Therefore the economic benefit from the use of a single inhalation anesthetic both as an induction drug and as a drug anesthetic drug has not been proved clinically and from an economic point of view that may require individual assessment of costs on the basis of regions of the Russian Federation or a particular institution.

1. Baum J.A. Low-fl ow anaesthesia. // Eur. J. Anaesthesiol. — 1996 Sep. — Vol. 13(5). — P.432.

2. Bilotta F., Doronzio A., Cuzzone V., et al. Early Postoperative Cognitive Recovery and Gas Exchange Patterns Aſt er Balanced Anesthesia With Sevofl urane or Desfl urane and Obese Patients Undergoing Craniotomy. // J NeurosurgAnesthesiol. 2009 Jul;21(3):207-13.

3. Brain market research on behalf of Baxter Healthcare, March 2011. Baxter, data on fi le 2012.

4. Chen X. et al. Th e recovery of cognitive function aſt er general anesthesia in elderly patients: a comparison of desfl urane and sevofl urane. // AnesthAnalg 2001,93:1489-1493.

5. Droh R., Rolly G., Schepp R. Practical experience with more than 60,000 closed circuit anesthesias. Traditional and future implications of the closed circuit concept // ActaAnaesthesiol. Belg. — 1984/ — Vol/ 35(4)/ — P. 265-272.

6. Dupont J., Tavernier B., Ghosez Y., et al. Recovery aſt er anaesthesia for pulmonary surgery: desfl urane, sevofl urane and isofl urane. // Br J Anaesth. 1999 Mar;82(3):355-9.

7. Eger E.I., Saidman L.J. Illustrations of inhaled anesthetic uptake, including intertissue diff usion to and from fat. // AnesthAnalg 2005; 100:1020-1033.

8. Eger El ll.,Weiskopf R.B., Eisenkraſt J.B. Th e pharmacology of inhaled anesthetics, An Antonio, Texas; 2002.

9. Golembiewski J. Economic considerations in the use of inhaled anesthetic agents. // Am J Health-Syst Pharm—Vol 67 Apr 15, 2010 Suppl 4.

10. Heavner J.E., Kaye A.D., Lin B.K., et al. Recovery of elderly patients from two or more hours of desfl urane or sevofl urane anaesthesia. Br J Anaesth 2003;91:502-506.

11. http://www.artongas.ru/medicine.html

12. Macario A., Vitez T.S., Dunn B., McDonald T. Where are the costs in perioperative care? Analysis of hospital costs and charges for inpatient surgical care // Anesthesiology. — 1995/ — Vol. 83(6). — P.1138—1144.

13. McKay R.E., Malhotra A., Cakmakkaya O.S., et al. Eff ects of increased body mass index and anaesthetic duration on recovery of protective airway refl exes aſt er sevofl urane vs. desfl urane. // Br J Anaesth 2010 Feb; 104(2):175-82.

14. Strum E., Szenohradszki J., Kaufman W., et al. Emergence and recovery characteristics of desfl urane versus sevofl urane in morbidly obese adult surgical patients: A prospective, randomized study. // AnesthAnalg 2004;99:1848-1853.

15. Vecil M., Di Stefano C., Zorzi F., et al. Low fl ow, minimal fl ow and closed circuit system inhalational anesthesia in modern clinical practice. Signa Vitae 2008;3:S33-S36.

16. Young C.J., Apfelbaum J.L. Inhalational anesthetics: desfl urane and sevofl urane. J ClinAnesth 1995;7:564-577.

17. Анестезиология: национальное руководство / Под общей ред. А.А. Бунатяна, В.М. Мизикова. — М.:ГЕОТАР-Медиа, 2011. — 1104 с.

18. Базовый курс анестезиолога. / Руководство Всемирной федерации общества анестезиологов (WFSA). Под общей редакции Маккормика Б., Недашковского Э.В., Кузькова В.В., 2013.,http://far.org.ru/fi les/Update_in_Anaesthesia_base.pdf.

19. Инструкция по медицинскому применению лекарственного препарата СЕВОРАН.

20. Инструкция по медицинскому применению лекарственного препарата СУПРАН.

21. Практическое руководство по анестезиологии / Под ред. В.В. Лихванцева. — 2-е изд., перераб. и доп. — М.: ООО «Медицинское информационное агентство», 2011. — 552 с.:ил.

22. Тарифы на медицинские услуги Московского городского фонда ОМС, введённые в действие с 01.04.2014 г. http://www.mgfoms.ru.

23. Ягудина Р.И., Куликов А.Ю., Серпик В.Г. Дисконтирование при проведении фармакоэкономических исследований. // Фармакоэкономика. 2009; №4: c.10-13.

24. Odin I, Feiss P. Low fl ow and economics of inhalational anesthesia. Balliere’sBestPracticeinClinicalAnesthesiology. 2005;19:399-413.

25. Meyer T. Managing inhaled anesthesia: challenges from a health-system pharmacist’s perspective. AmericanJournalofHealth-SystemPharmacy. 2010;67:S4-S8.

26. Dion P. Th e cost of anaesthetic vapors. Canada Journal of Anaesthesia. 1992;39(6):633.

27. Планирование и проведение клинических исследований лекарственных средств, г. Москва, 2000 г. ООО «Издательство ОКИ», под ред. Ю.Б. Белоусова.

28. Белоусов Ю.Б., Белоусов Д.Ю. Учебное пособие «Основы фармакоэкономических исследований», М.2000 г. Национальный фонд содействия научным и клиническим исследованиям при РГМУ.

29. Клинические испытания лекарств, под ред. Мальцев В.И., Ефимцева Т.К., Белоусов Ю.Б. Киев. Морион: 2002 г.

30. Мальцев В.И., Ефимцева Т.К., Белоусов Д.Ю. Типы иметоды проведения фармакоэкономических исследований. // Украинский медицинский журнал. 2002. № 5. С. 59.

31. Основы клинической фармакотерапии: Рук. для практикующих врачей / Ю.Б. Белоусов, М.В. Леонова, Д.Ю. Белоусов, А.Н. Вялков и др.; Под общ. Ред. Ю.Б. Белоусова, М.В. Леоновой. — М.: Бионика, 2002. — 368 с. — (Рациональная фармакотерапия: Сер. Рук. практикующих врачей; Т.1).

32. Белоусов Ю.Б., Вялков А.И., Белоусов Д.Ю. Клинический проектный менеджмент: учебное пособие / Под ред. Вялкова А. И., Белоусова Ю. Б., -М.: ГЭОТАР-МЕД, 2003. -448 с.

33. Белоусов Д.Ю., Куликов А.Ю., Колбин А.С., Карпов О.И., Быков А.В., Толкушин А.Г. Фармакоэкономика: зачем, где и как проводить фармакоэкономические исследования? // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2010 г. Т. 3. № 2, стр. 19-21.

34. Колбин А.С., Павлыш А.В., Курылев А.А., Белоусов Д.Ю. Исследования сравнительной эффективности. // Качественная клиническая практика, 2013 г., №1, стр. 70-77.

35. Колбин А.С., Зырянов С.К., Белоусов Д.Ю. Основные понятия в оценке медицинских технологий: метод. пособие / под общ. ред. Колбина А. С., Зырянова С. К., Белоусова Д. Ю. — Москва: Издательство ОКИ, 2013. — 42 с.: ил.

36. Колбин А.С., Павлыш А.В., Курылев А.А., Белоусов Д.Ю. Сравнительный анализ оценки медицинских технологий. // Армянский медицинский реферативный журнал, Ереван, №10, 2013 г., стр. 160-166.

37. Weinberg L., Story D., Nam J., McNicols L. Pharmacoeconomics of volatile inhalational anaesthetic agents: an 11-year retrospective analysis. Anaesthesia and Intensive Care. 2010; 38(5)849-854.

38. Ultane (sevofl urane) volatile liquid for inhalation. Food and Drug Administration. From http://www.accessdata.fda.gov/drugsatfda_docs/ label/2006/020478s016lbl.pdf. Accessed 8/31/2012.

39. White D.C. Closed and Low Flow System Anaesthesia. // Curr. Anaesth. Crit. Care. — 1992. — v. 3. — pp. 98-107.